In many GI tumors, the NRF2 pathway is constitutively activated due to oncogenic mutations or persistent oxidative stress, leading to the overexpression of numerous antioxidant genes (including GSH synthesis enzymes, the thioredoxin system, and GPX4), thereby building a powerful anti-ferroptotic barrier [89]. This evidence concerns the gene GPX4 and digestive system neoplasm.